Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis
Related Experiment Video
Updated: Nov 23, 2025

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Kazutaka Fukumura1, Prit Benny Malgulwar1, Grant M Fischer1,2,3
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Abstract:
The deadly complication of brain metastasis (BM) is largely confined to a relatively narrow cross-section of systemic malignancies, suggesting a fundamental role for biological mechanisms shared across commonly brain metastatic tumor types. To identify and characterize such mechanisms, we performed genomic, transcriptional, and proteomic profiling using whole-exome sequencing, mRNA-seq, and reverse-phase protein array analysis in a cohort of the lung, breast, and renal cell carcinomas consisting of BM and patient-matched primary or extracranial metastatic tissues. While no specific genomic alterations were associated with BM, correlations with impaired cellular immunity, upregulated oxidative phosphorylation (OXPHOS), and canonical oncogenic signaling pathways including phosphoinositide 3-kinase (PI3K) signaling, were apparent across multiple tumor histologies. Multiplexed immunofluorescence analysis confirmed significant T cell depletion in BM, indicative of a fundamentally altered immune microenvironment. Moreover, functional studies using in vitro and in vivo modeling demonstrated heightened oxidative metabolism in BM along with sensitivity to OXPHOS inhibition in murine BM models and brain metastatic derivatives relative to isogenic parentals. These findings demonstrate that pathophysiological rewiring of oncogenic signaling, cellular metabolism, and immune microenvironment broadly characterizes BM. Further clarification of this biology will likely reveal promising targets for therapeutic development against BM arising from a broad variety of systemic cancers.
Insights
Brain metastasis (BM) involves shared biological mechanisms across cancers. Studies reveal impaired immunity, increased oxidative phosphorylation, and altered signaling pathways characterize BM, suggesting new therapeutic targets.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Pathology
Background:
- Brain metastasis (BM) is a severe complication of systemic cancers.
- Understanding shared mechanisms driving BM is crucial for developing effective therapies.
Purpose of the Study:
- To identify and characterize the biological mechanisms underlying brain metastasis.
- To investigate genomic, transcriptional, and proteomic profiles of brain metastatic tumors.
Main Methods:
- Genomic, transcriptional, and proteomic profiling (whole-exome sequencing, mRNA-seq, RPPA).
- Analysis of lung, breast, and renal cell carcinomas with BM and matched controls.
- Multiplexed immunofluorescence and in vitro/in vivo functional studies.
Main Results:
- No specific genomic alterations linked to BM.
- Correlations found with impaired cellular immunity, upregulated oxidative phosphorylation (OXPHOS), and PI3K signaling.
- BM tissues showed T cell depletion and heightened oxidative metabolism, with sensitivity to OXPHOS inhibition.
Conclusions:
- Pathophysiological rewiring of signaling, metabolism, and immune microenvironment characterizes BM.
- These shared alterations offer potential therapeutic targets for diverse systemic cancers with BM.

